The financing aims to strengthen Suneva Medical’s revenue growth and further supports the ongoing commercialization of the company’s flagship products, Bellafill® and Regenica®.
Led by Nicholas L. Teti, Jr., Chairman and Chief Executive Officer, Suneva Medical focuses on developing, manufacturing and commercializing novel, differentiated products for the general dermatology and aesthetic markets. It currently offers Bellafill, a FDA approved dermal filler for the treatment of nasolabial folds, or smile lines, and facial acne scars, and the Regenica® skin care line, to enhance skin’s natural repair and renewal mechanisms.
In conjunction with the investment, Essex Woodlands will receive one seat on Suneva Medical’s board of directors and an independent seat will also be appointed. In addition to Essex Woodlands, other major equity shareholders include HealthCare Royalty Partners, Almirall, S.A. and Polaris Partners.
FinSMEs
14/06/2016